Planning Directions’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-2,920
Closed -$417K 84
2024
Q2
$417K Buy
2,920
+4
+0.1% +$530 0.28% 46
2024
Q1
$374K Buy
2,916
+112
+4% +$13.3K 0.26% 50
2023
Q4
$290K Hold
2,804
0.21% 56
2023
Q3
$255K Buy
2,804
+2
+0.1% +$176 0.2% 51
2023
Q2
$227K Buy
2,802
+4
+0.1% +$327 0.17% 60
2023
Q1
$223K Buy
+2,798
New +$198K 0.17% 64

Other funds holding NVO

Planning Directions's NVO Position: Q3 2024 in Review

Planning Directions sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 2,920 shares — an estimated $417K sold.

Planning Directions first reported a position in NVO in Q1 2023 and held it in 6 quarters. The position peaked at $417K in Q2 2024. 1,784 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • Planning Directions reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
  • Planning Directions sold 2,920 Novo Nordisk shares in Q3 2024, an estimated $417K.
  • Planning Directions first reported a position in Novo Nordisk in Q1 2023 and held it in 6 quarters.
  • Planning Directions's Novo Nordisk position peaked at $417K in Q2 2024.
  • 1,784 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Planning Directions's 13F filing for Q3 2024, filed 7 Nov 2024.